Protagonist Therapeutics, Inc. (PTGX)

In October 2025, Protagonist announced new data from Phase 2b ANTHEM-UC study of icotrokinra in ulcerative colitis, showing sustained and clinically meaningful results. Johnson & Johnson initiated the ICONIC-UC Phase 3 trial for ulcerative colitis and the ICONIC-CD Phase 2b/3 trial for Crohn's disease. In August 2025, Rusfertide received Breakthrough Therapy Designation for the treatment of erythrocytosis in patients with polycythemia vera. In June 2025, Protagonist announced the nomination of PN-477, an oral and injectable GLP-1R, GIPR, and GCGR triple agonist peptide development candidate for obesity. In October 2025, Protagonist Therapeutics' stock surged due to heightened takeover speculation. In August 2025, the company reported its second-quarter 2025 financial results, with an earnings per share (EPS) of ($0.55). As of October 2025, analysts generally have a "Moderate Buy" or "Strong Buy" consensus rating for PTGX, with an average price target around $74.00.

Protagonist Therapeutics' products and services are not typically subject to demand seasonality. The demand for its drug candidates, once approved, would be driven by disease prevalence, treatment guidelines, and market access, rather than seasonal fluctuations. No specific information indicating demand seasonality for Protagonist Therapeutics' products or services was found.

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel peptide-based therapeutics. The company operates in the Health Care sector, specifically in the Biotechnology: Pharmaceutical Preparations industry, leveraging its proprietary peptide technology platform to create new chemical entities for unmet medical needs. Its major product pipeline includes Rusfertide (PTG-300), an injectable mimetic of hepcidin in Phase 3 trials for polycythemia vera and other blood disorders; Icotrokinra (formerly JNJ-2113 or PTG-200), an orally delivered Interleukin-23 receptor (IL-23R) antagonist in Phase 3 trials for inflammatory conditions; PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist that has completed Phase 2 clinical trials in patients with moderate to severe ulcerative colitis; PN-881, an IL-17 oral peptide antagonist; an oral metabolic/obesity peptide program; and an oral hepcidin mimetic/ferroportin blocker program in the pre-clinical stage.

Protagonist Therapeutics operates in innovation hubs in the U.S. and Australia. The company's corporate headquarters are located in Newark, California, USA. It also maintains an R&D office in Brisbane, Australia, where its discovery platform was initially conceived at the University of Queensland.

Protagonist Therapeutics has maintained a positive brand reputation over the past year, largely driven by its scientific advancements and strategic partnerships. In 2025, Protagonist Therapeutics was recognized as one of the top 5 Most Innovative Biotechnology companies by Fast Company. The consistent reporting of promising clinical data for its lead product candidates, Rusfertide and Icotrokinra, has bolstered its reputation within the biopharmaceutical community. Its lucrative partnerships with Johnson & Johnson and Takeda for the development and commercialization of its drugs further enhance its standing. The interest from a major healthcare giant like Johnson & Johnson in a potential acquisition also reflects positively on Protagonist's assets and strategic value.

The ownership of Protagonist Therapeutics, Inc. is distributed among institutional investors, individual shareholders, and company insiders. Key institutional holders include BlackRock Inc., Farallon Capital Management LLC, RTW Investments LP, Vanguard Group Inc., Deep Track Capital LP, BVF Inc/il, State Street Corp, UBS Group AG, and Johnson & Johnson. Julie Papanek is a significant individual shareholder, owning 2.45 million shares, representing 3.94% of the company. Company officers and directors also hold shares as insiders.